Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma.

MLA

Donson, Andrew M., et al. “Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma.” Molecular Cancer Therapeutics, vol. 17, no. 9, Sept. 2018, pp. 1984–94. EBSCOhost, https://doi.org/10.1158/1535-7163.MCT-17-1185.

APA

Donson, A. M., Amani, V., Warner, E. A., Griesinger, A. M., Witt, D. A., Levy, J. M. M., Hoffman, L. M., Hankinson, T. C., Handler, M. H., Vibhakar, R., Dorris, K., & Foreman, N. K. (2018). Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma. Molecular Cancer Therapeutics, 17(9), 1984–1994. https://doi.org/10.1158/1535-7163.MCT-17-1185

Chicago

Donson, Andrew M, Vladimir Amani, Elliot A Warner, Andrea M Griesinger, Davis A Witt, Jean M Mulcahy Levy, Lindsey M Hoffman, et al. 2018. “Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma.” Molecular Cancer Therapeutics 17 (9): 1984–94. doi:10.1158/1535-7163.MCT-17-1185.